دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
The Platinum Hall of Fame
doi : 10.1016/j.eururo.2023.01.019
Volume 83, Issue 3, March 2023, Pages e63-e72
Opening the Horizons of Functional Urology and Neurourology to Robot-assisted Surgery
Sabrina De Cillis a,b,*, Paolo Geretto a,c , Veronique Phe
doi : 10.1016/j.eururo.2022.12.011
Volume 83, Issue 3, March 2023, Pages 189-190
The Future of Medical Devices in Europe Is at Stake: Concerns over the Implementation of the Medical Devices Regulation 2017/745
Simone Albisinni a,*, Jens Rassweiler b , Hendrik van Poppel
doi : 10.1016/j.eururo.2022.12.015
Volume 83, Issue 3, March 2023, Pages 191-192
High-quality Transurethral Resection of Bladder Tumour Needs Additional Forms of Tumour Delineation
Arnulf Stenzl a,*, Morgan Roupreˆt b , J. Alfred Witjes c , Paolo Gontero
doi : 10.1016/j.eururo.2022.11.017
Volume 83, Issue 3, March 2023, Pages 193-194
Progression-free Survival After Second Line of Therapy for Metastatic Clear Cell Renal Cell Carcinoma in Patients Treated with First-line Immunotherapy Combinations
Kelly N. Fitzgerald a,y, Cihan Duzgol b,y, Andrea Knezevic c , Natalie Shapnik a , Ritesh Kotecha a , David H. Aggen a , Maria I. Carlo a , Neil J. Shah a , Martin H. Voss a , Darren R. Feldman a , Robert J. Motzer a , Chung-Han Lee
doi : 10.1016/j.eururo.2022.10.017
Volume 83, Issue 3, March 2023, Pages 195-199
Immunotherapy (IO)-based combinations used to treat metastatic clear cell renal cell carcinoma (ccRCC) include dual immune checkpoint inhibition with ipilimumab and nivolumab (IO/IO) and several combinations of vascular endothelial growth factor receptor–targeting tyrosine kinase inhibitors (TKIs) with an immune checkpoint inhibitor (TKI/IO). IO/IO and TKI/IO approaches have not been compared directly, and it is unknown whether patients who do not respond to first-line IO/IO can salvage long-term survival by receiving a second-line TKI.
Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib
Andrea Loehr a , Arif Hussain b , Akash Patnaik c , Alan H. Bryce d , Daniel Castellano e , Albert Font f , Jeremy Shapiro g , Jingsong Zhang h , Brieuc Sautois i , Nicholas J. Vogelzang j , Gurkamal Chatta k , Kevin Courtney l , Andrea Harzstark m , Francesco Ricci n , Darrin Despain o , Simon Watkins p , Charmin King q , Minh Nguyen a , Andrew D. Simmons a , Simon Chowdhury r,s , Wassim Abida t,*
doi : 10.1016/j.eururo.2022.09.010
Volume 83, Issue 3, March 2023, Pages 200-209
Poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors are approved in the USA for the treatment of patients with BRCA1 or BRCA2 (BRCA) mutated (BRCA+) metastatic castration-resistant prostate cancer (mCRPC).
BRCA Reversion Mutations in Metastatic Castration-Resistant Prostate Cancer
Gillian Vandekerkhove
doi : 10.1016/j.eururo.2022.09.031
Volume 83, Issue 3, March 2023, Pages 210-211
Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial
Martin Bo ̈gemann a,*, Neal D. Shore b , Matthew R. Smith c , Teuvo L.J. Tammela d , Albertas Ulys e , Egils Vjaters f , Sergey Polyakov g , Mindaugas Jievaltas h , Murilo Luz i , Boris Alekseev j , Thierry Lebret k , Martin Schostak l , Frank Verholen m , Marie-Aude Le Berre n , Shankar Srinivasan o , Jorge Ortiz o , Ateesha F. Mohamed o , Toni Sarapohja p , Karim Fizazi
doi : 10.1016/j.eururo.2022.07.018
Volume 83, Issue 3, March 2023, Pages 212-221
Be Careful Not To ARAMIS the Point
Ian D. Davis
doi : 10.1016/j.eururo.2022.09.019
Volume 83, Issue 3, March 2023, Pages 222-223
B7-H3 as a Therapeutic Target in Advanced Prostate Cancer
Christina Guo a,b,y, Ines Figueiredo a,y, Bora Gurel a,y, Antje Neeb a , George Seed a , Mateus Crespo a , Suzanne Carreira a , Jan Rekowski a , Lorenzo Buroni a , Jon Welti a , Denisa Bogdan a , Lewis Gallagher a , Adam Sharp a,b , Maria D. Fenor de la Maza a,b , Pasquale Rescigno c , Daniel Westaby a,b , Khobe Chandran a,b , Ruth Riisnaes a , Ana Ferreira a , Susana Miranda a , Bianca Calı` d , Andrea Alimonti d,e,f , Silvia Bressan d,g , Alana H.T. Nguyen h , Michael M. Shen h , Jessica E. Hawley h,i , Aleksandar Obradovic h , Charles G. Drake h,j , Claudia Bertan a , Chloe Baker a , Nina Tunariu a,b , Wei Yuan a , Johann S. de Bono
doi : 10.1016/j.eururo.2022.09.004
Volume 83, Issue 3, March 2023, Pages 224-238
B7-H3 is a cell surface immunomodulatory glycoprotein overexpressed in prostate cancers (PCs). Understanding its longitudinal expression at emergence of castration resistance and association with tumour genomics are critical to the development of and patient selection for B7-H3 targeted therapies.
B7-H3 and Prostate Cancer: New Therapeutic Dance Partners
Eugene Shenderov a,b,*, Emmanuel S. Antonarakis
doi : 10.1016/j.eururo.2022.10.019
Volume 83, Issue 3, March 2023, Pages 239-240
Genetic Risk Prediction for Prostate Cancer: Implications for Early Detection and Prevention
Tyler M. Seibert a,*, Isla P. Garraway b , Anna Plym c , Brandon A. Mahal d , Veda Giri e , Michelle F. Jacobs f , Heather H. Cheng g , Stacy Loeb h , Brian T. Helfand i , Rosalind A. Eeles j , Todd M. Morgan
doi : 10.1016/j.eururo.2022.12.021
Volume 83, Issue 3, March 2023, Pages 241-248
Prostate cancer (PCa) is a leading cause of death and partially heritable. Genetic risk prediction might be useful for strategies to reduce PCa mortality through early detection and prevention.
Vector Prostate Biopsy: A Novel Magnetic Resonance Imaging/Ultrasound Image Fusion Transperineal Biopsy Technique Using Electromagnetic Needle Tracking Under Local Anaesthesia
Peter Fletcher a,*, Marta De Santis b , Simona Ippoliti c , Luca Orecchia d , Philip Charlesworth e , Tristan Barrett a,e , Christof Kastner
doi : 10.1016/j.eururo.2022.12.007
Volume 83, Issue 3, March 2023, Pages 249-256
Prostate magnetic resonance imaging (MRI) is now standard for assessment of suspected prostate cancer (PCa). A variety of approaches to MRI-based targeting has revolutionised prostate biopsies.
Family History of Prostate Cancer and Survival Outcomes in the UK Genetic Prostate Cancer Study
Mark N. Brook a,*, Holly Nı � Raghallaigh a , Koveela Govindasami a , Tokhir Dadaev a , Reshma Rageevakumar a , Diana Keating a , Nafisa Hussain a , Andrea Osborne a , Artitaya Lophatananon b , UKGPCS Collaborators, Kenneth R. Muir b , Zsofia Kote-Jarai a , Rosalind A. Eeles
doi : 10.1016/j.eururo.2022.11.019
Volume 83, Issue 3, March 2023, Pages 257-266
A family history (FH) of prostate cancer (PrCa) is associated with an increased likelihood of PrCa diagnosis. Conflicting evidence exists regarding familial PrCa and clinical outcomes among PrCa patients, including all-cause mortality/overall survival (OS), PrCa-specific survival (PCSS), aggressive histology, and stage at diagnosis.
Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022
Silke Gillessen a,b,*, Alberto Bossi c , Ian D. Davis d , Johann de Bono e,f , Karim Fizazi g , Nicholas D. James e , Nicolas Mottet h , Neal Shore i,j , Eric Small k , Mathew Smith l , Christopher Sweeney m , Bertrand Tombal n , Emmanuel S. Antonarakis o , Ana M. Aparicio p , Andrew J. Armstrong q
doi : 10.1016/j.eururo.2022.11.002
Volume 83, Issue 3, March 2023, Pages 267-293
Innovations in imaging and molecular characterisation and the evolution of new therapies have improved outcomes in advanced prostate cancer. Nonetheless, we continue to lack high-level evidence on a variety of clinical topics that greatly impact daily practice. To supplement evidence-based guidelines, the 2022 Advanced Prostate Cancer Consensus Conference (APCCC 2022) surveyed experts about key dilemmas in clinical management.
Re: Modern Imaging in Prostate Cancer: Do We Treat Patients or Their Scans?
Chris H. Bangma
doi : 10.1016/j.eururo.2022.11.014
Volume 83, Issue 3, March 2023, Page 294
Re: Randomized Trial of Ultralow vs Standard Pneumoperitoneum during Robotic Prostatectomy
Claire M. de la Calle Christian P. Pavlovich
doi : 10.1016/j.eururo.2022.12.004
Volume 83, Issue 3, March 2023, Page 295
Re: The Natural History of Untreated Biopsy Grade Group Progression and Delayed Definitive Treatment for Men on Active Surveillance for Early-stage Prostate Cancer
Levent Türkeri
doi : 10.1016/j.eururo.2022.12.005
Volume 83, Issue 3, March 2023, Page 296
Re: Oncological Benefit of Re-resection for T1 Bladder Cancer: A Comparative Effectiveness Study
Marko Babjuk
doi : 10.1016/j.eururo.2022.11.011
Volume 83, Issue 3, March 2023, Page 297
Re: Adjuvant Atezolizumab Versus Placebo for Patients with Renal Cell Carcinoma at Increased Risk of Recurrence Following Resection (IMmotion010): A Multicentre, Randomised, Double-blind, Phase 3 Trial
Zhenjie Wu a Linhui Wang a Savio D. Pandolfo b Riccardo Autorino
doi : 10.1016/j.eururo.2022.11.010
Volume 83, Issue 3, March 2023, Pages 297-298
Re: A Randomized Trial of PHOTOdynamic Surgery in Non–muscle-invasive Bladder Cancer
Marie-Pier St-Laurent * Jonathan Suderman Peter C. Black
doi : 10.1016/j.eururo.2022.12.018
Volume 83, Issue 3, March 2023, Pages 298-299
Re: Umberto Capitanio, Jens Bedke, Laurence Albiges, et al. A Renewal of the TNM Staging System for Patients with Renal Cancer To Comply with Current Decision-making: Proposal from the European Association of Urology Guidelines Panel. Eur Urol. 2023;83:3–5
Yaxiong Tang Xu Hu Kan Wu Yanxiang Shao Xiang Li
doi : 10.1016/j.eururo.2022.11.026
Volume 83, Issue 3, March 2023, Page e73
Reply to Yaxiong Tang, Xu Hu, Kan Wu, Yanxiang Shao, and Xiang Li’s Letter to the Editor re: Umberto Capitanio, Jens Bedke, Laurence Albiges, et al. A Renewal of the TNM Staging System for Patients with Renal Cancer To Comply with Current Decision-making: Proposal from the European Association of Urology Guidelines Panel. Eur Urol. 2022;83:3–5
Umberto Capitanio a,b,* Jens Bedke c,d Laurence Albiges e Alessandro Volpe f Rachel H. Giles g Milan Hora h Lorenzo Marconi i Tobias Klatte j Yasmin Abu-Ghanem k Saeed Dabestani l Sergio Fernández Pello m Fabian Hofmann n Teele Kuusk o Riccardo Campi p,q Rana Tahbaz j Thomas Powles r Börje Ljungberg s Axel Bex
doi : 10.1016/j.eururo.2022.12.001
Volume 83, Issue 3, March 2023, Pages e74-e75
Re: Andrea Loehr, Arif Hussain, Akash Patnaik, et al. Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.09.010
Feng Qi Zicheng Xu * Qing Zou
doi : 10.1016/j.eururo.2022.12.024
Volume 83, Issue 3, March 2023, Pages e76-e77
Reply to Feng Qi, Zicheng Xu, and Qing Zou’s Letter to the Editor re: Andrea Loehr, Arif Hussain, Akash Patnaik, et al. Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.09.010
Andrea Loehr a Simon Chowdhury b,c Wassim Abida
doi : 10.1016/j.eururo.2022.12.023
Volume 83, Issue 3, March 2023, Page e78
Re: Mathew D. Sorensen, Jonathan D. Harper, Michael S. Borofsky, et al. Removal of Small, Asymptomatic Kidney Stones and Incidence of Relapse. N Engl J Med 2022;387:506–13
Wei Wang * Guowei Shi
doi : 10.1016/j.eururo.2022.11.021
Volume 83, Issue 3, March 2023, Page e79
Reply to Wei Wang and Guowei Shi’s Letter to the Editor re: Mathew D. Sorensen, Jonathan D. Harper, Michael S. Borofsky, et al. Removal of Small, Asymptomatic Kidney Stones and Incidence of Relapse. N Engl J Med 2022;387:506–13
Reply to Wei Wang and Guowei Shi’s Letter to the Editor re: Mathew D. Sorensen, Jonathan D. Harper, Michael S. Borofsky, et al. Removal of Small, Asymptomatic Kidney Stones and Incidence of Relapse. N Engl J Med 2022;387:506–13
doi : 10.1016/j.eururo.2022.12.002
Volume 83, Issue 3, March 2023, Pages e80-e81
Re: Laura S. Mertens, Richard P. Meijer, J. Alfred Witjes. Positron Emission Tomography/Computed Tomography for Staging of Bladder Cancer: A Continuing Clinical Controversy. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.09.017
Fredrik Liedberg a,* Elin Trägårdh
doi : 10.1016/j.eururo.2022.11.022
Volume 83, Issue 3, March 2023, Pages e82-e83
Re: George J. Netto, Mahul B. Amin, Eva M. Compérat, et al. Prostate Adenocarcinoma Grade Group 1: Rationale for Retaining a Cancer Label in the 2022 World Health Organization Classification. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.09.015
Alessia Cimadamore a Antonio Lopez-Beltran b Liang Cheng c Rodolfo Montironi
doi : 10.1016/j.eururo.2022.11.024
Volume 83, Issue 3, March 2023, Pages e84-e86
Corrigendum to “Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study� [Eur Urol 83 (2023) 15–26]
Evan Y. Yu a,*, Josep M. Piulats b , Gwenaelle Gravis c , Peter C.C. Fong d,e , Tilman Todenho ̈fer f , Brigitte Laguerre g , Jose A. Arranz h , Stephane Oudard i , Christophe Massard j,k , Julia Heinzelbecker l,m , Luke T. Nordquist n , Joan Carles o , Michael P. Kolinsky p , Marinela Augustin q , Howard Gurney r , Ali Tafreshi s , Xin Tong Li t , Ping Qiu t , Christian H. Poehlein t , Charles Schloss t , Johann S. de Bono
doi : 10.1016/j.eururo.2022.11.025
Volume 83, Issue 3, March 2023, Page e87
Corrigendum to “Young Age on Starting Prostate-specific Antigen Testing Is Associated with a Greater Reduction in Prostate Cancer Mortality: 24-Year Follow-up of the Göteborg Randomized Population-based Prostate Cancer Screening Trial” [Eur Urol (2022)]
Sigrid V. Carlsson a,b,c , Rebecka Arnsrud Godtman c,d , Carl-Gustav Pihl e , Andrew Vickers b , Hans Lilja a,f,g,h , Jonas Hugosson c,d , Marianne Ma ÌŠ nsson c,*
doi : 10.1016/j.eururo.2022.11.020
Volume 83, Issue 3, March 2023, Page e88
